TABLE 1.
Baseline characteristics in subjects with HBV not on NAs who did not meet the 2018 AASLD HBV treatment guidelines and developed HCC (no NA/HCC), subjects with HBV on NAs who developed HCC (NA/HCC), and subjects with HBV not on NAs who did not meet the 2018 AASLD HBV treatment guidelines and did not develop HCC (no NA/no HCC)
| Factor | No NA/HCC (n = 133) n (%) or median (IQR) | NA/HCC (n = 209) n (%) or median (IQR) | No NA/No HCC (n = 1110) n (%) or median (IQR) | p‐Values a |
|---|---|---|---|---|
| Male | 91 (68%) | 165 (79%) | 526 (47%) | 0.04, <0.001 |
| Female | 42 (32%) | 44 (21%) | 584 (53%) | 0.04, <0.001 |
| Asian | 61 (46%) | 165 (79%) | 772 (69%) | <0.001, <0.001 |
| White | 32 (24%) | 14 (7%) | 119 (11%) | <0.001, <0.001 |
| Hispanic | 5 (4%) | 2 (1%) | 4 (0.4%) | 0.1, 0.001 |
| F2/F3 fibrosis | 3 (2%) | 30 (14%) | 12 (1%) | <0.001, 0.2 |
| Cirrhosis | 115 (86%) | 163 (78%) | 111 (10%) | 0.06, <0.001 |
| Age (years) | 61 (55–69) | 58 (50–67) | 42 (33–53) | 0.03, <0.001 |
| ALT (IU/L) | 67 (48–107) | 71 (51–109) | 33 (26–41) | 0.6, <0.001 |
| HBV DNA (mIU/ml) | Undetected (undetected–undetected) | 20 (undetected–51) | Undetected (undetected–undetected) | <0.001, <0.001 |
| ALP (U/L) | 124 (87–177) | 131 (113–131) | 76 (61–86) | 0.7, <0.001 |
| AST (IU/L) | 70 (50–115) | 77 (47–128) | 26 (21–30) | 0.5, <0.001 |
| TB (mg/dl) | 1.01 (0.7–1.9) | 0.9 (0.7–1.6) | 0.7 (0.5–0.9) | 0.09, <0.001 |
| INR | 1.26 (1.1–3.04) | 1.2 (1.1–1.4) | 1.09 (1.06–1.1) | 0.3, <0.001 |
| NAs (mmol/L) | 137 (136–144) | 139 (137–144) | 139 (138–140) | <0.001, <0.001 |
| Platelets (K/ul) | 143 (91–200) | 163 (120–205) | 217 (187–249) | 0.01, <0.001 |
| Albumin (g/dl) | 3.3 (2.8–3.7) | 3.8 (3.3–4) | 4.2 (3.9–4.4) | <0.001, <0.001 |
| ALD | 48 (36%) | 46 (22%) | 10 (1%) | 0.006, <0.001 |
| HCV | 16 (15%) | 37 (18%) | 62 (5%) | 0.2, 0.007 |
| NAFLD | 34 (22%) | 36 (17%) | 92 (8%) | 0.07, <0.001 |
| HIV | 3 (2%) | 1 (1%) | 3 (0.3%) | 0.3, 0.02 |
| HDV | 0 (0%) | 1 (1%) | 0 (0%) | 1, 1 |
Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALD, alcoholic‐associated liver disease; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; INR, international normalized ratio; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; TB, total bilirubin.
p‐Values comparing NA/HCC with no NA/HCC, and no NA/no HCC with no NA/HCC, respectively.